-
1
-
-
79958281016
-
Novel antibodies against follicular non-Hodgkin's lymphoma
-
van Meerten T, Hagenbeek A. Novel antibodies against follicular non-Hodgkin's lymphoma. Best Pract. Res. Clin. Haematol. 24(2), 231-256 (2011).
-
(2011)
Best Pract. Res. Clin. Haematol.
, vol.24
, Issue.2
, pp. 231-256
-
-
van Meerten, T.1
Hagenbeek, A.2
-
4
-
-
0345337254
-
Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program
-
McLaughlin P, Grillo-López AJ, Link BK et al. Rituximab chimeric antiCD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J. Clin. Oncol. 16(8), 2825-2833 (1998).
-
(1998)
J. Clin. Oncol.
, vol.16
, Issue.8
, pp. 2825-2833
-
-
McLaughlin, P.1
Grillo-López, A.J.2
Link, B.K.3
-
5
-
-
28544435078
-
Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group
-
Hiddemann W, Kneba M, Dreyling M et al. Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 106(12), 3725-3732 (2005).
-
(2005)
Blood
, vol.106
, Issue.12
, pp. 3725-3732
-
-
Hiddemann, W.1
Kneba, M.2
Dreyling, M.3
-
6
-
-
33646004738
-
CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group
-
Pfreundschuh M, Trümper L, Osterborg A et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol. 7(5), 379-391 (2006).
-
(2006)
Lancet Oncol.
, vol.7
, Issue.5
, pp. 379-391
-
-
Pfreundschuh, M.1
Trümper, L.2
Osterborg, A.3
-
7
-
-
20144376591
-
Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
-
Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J. Clin. Oncol. 23(9), 1984-1992 (2005).
-
(2005)
J. Clin. Oncol.
, vol.23
, Issue.9
, pp. 1984-1992
-
-
Lenz, G.1
Dreyling, M.2
Hoster, E.3
-
9
-
-
80051722000
-
Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders
-
Derby L, Czuczman MS. Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncol. 7(8), 963-979 (2011).
-
(2011)
Future Oncol.
, vol.7
, Issue.8
, pp. 963-979
-
-
Derby, L.1
Czuczman, M.S.2
-
10
-
-
84902819796
-
Advances and application of radioimmunotherapy in non-Hodgkin lymphoma
-
Stevens PL, Oluwole O, Reddy N. Advances and application of radioimmunotherapy in non-Hodgkin lymphoma. Am. J. Blood Res. 2(2), 86-97 (2012).
-
(2012)
Am. J. Blood Res.
, vol.2
, Issue.2
, pp. 86-97
-
-
Stevens, P.L.1
Oluwole, O.2
Reddy, N.3
-
11
-
-
49649120397
-
Tumor regression in cancer patients by very low doses of a T cell-engaging antibody
-
Bargou R, Leo E, Zugmaier G et al. Tumor regression in cancer patients by very low doses of a T cell-engaging antibody. Science 321(5891), 974-977 (2008).
-
(2008)
Science
, vol.321
, Issue.5891
, pp. 974-977
-
-
Bargou, R.1
Leo, E.2
Zugmaier, G.3
-
12
-
-
84864544136
-
Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma
-
Younes A, Kim S, Romaguera J et al. Phase I multidose-escalation study of the anti-CD19 maytansinoid immunoconjugate SAR3419 administered by intravenous infusion every 3 weeks to patients with relapsed/ refractory B-cell lymphoma. J. Clin. Oncol. 30(22), 2776-2782 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, Issue.22
, pp. 2776-2782
-
-
Younes, A.1
Kim, S.2
Romaguera, J.3
-
13
-
-
34249664979
-
Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies
-
Leonard JP, Goldenberg DM. Preclinical and clinical evaluation of epratuzumab (anti-CD22 IgG) in B-cell malignancies. Oncogene 26(25), 3704-3713 (2007).
-
(2007)
Oncogene
, vol.26
, Issue.25
, pp. 3704-3713
-
-
Leonard, J.P.1
Goldenberg, D.M.2
-
14
-
-
33748471355
-
Multicenter Phase II trial of immunotherapy with the humanized antiCD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma
-
Strauss SJ, Morschhauser F, Rech J et al. Multicenter Phase II trial of immunotherapy with the humanized antiCD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma. J. Clin. Oncol. 24(24), 3880-3886 (2006).
-
(2006)
J. Clin. Oncol.
, vol.24
, Issue.24
, pp. 3880-3886
-
-
Strauss, S.J.1
Morschhauser, F.2
Rech, J.3
-
15
-
-
80054098574
-
Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma
-
Micallef IN, Maurer MJ, Wiseman GA et al. Epratuzumab with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated diffuse large B-cell lymphoma. Blood 118(15), 4053-4061 (2011).
-
(2011)
Blood
, vol.118
, Issue.15
, pp. 4053-4061
-
-
Micallef, I.N.1
Maurer, M.J.2
Wiseman, G.A.3
-
16
-
-
77957272703
-
High rates of durable responses with antiCD22 fractionated radioimmunotherapy: results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma
-
Morschhauser F, Kraeber-Bodéré F, Wegener WA et al. High rates of durable responses with antiCD22 fractionated radioimmunotherapy: results of a multicenter, Phase I/II study in non-Hodgkin's lymphoma. J. Clin. Oncol. 28(23), 3709-3716 (2010).
-
(2010)
J. Clin. Oncol.
, vol.28
, Issue.23
, pp. 3709-3716
-
-
Morschhauser, F.1
Kraeber-Bodéré, F.2
Wegener, W.A.3
-
17
-
-
84860243682
-
Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/ refractory B-cell non-Hodgkin lymphoma
-
Ogura M, Hatake K, Ando K et al. Phase I study of anti-CD22 immunoconjugate inotuzumab ozogamicin plus rituximab in relapsed/ refractory B-cell non-Hodgkin lymphoma. Cancer Sci. 103(5), 933-938 (2012).
-
(2012)
Cancer Sci.
, vol.103
, Issue.5
, pp. 933-938
-
-
Ogura, M.1
Hatake, K.2
Ando, K.3
-
18
-
-
0034092593
-
A Phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19+, CD22+ B cell lymphoma
-
Messmann RA, Vitetta ES, Headlee D et al. A Phase I study of combination therapy with immunotoxins IgG-HD37-deglycosylated ricin A chain (dgA) and IgG-RFB4-dgA (Combotox) in patients with refractory CD19+, CD22+ B cell lymphoma. Clin. Cancer Res. 6(4), 1302-1313 (2000).
-
(2000)
Clin. Cancer Res.
, vol.6
, Issue.4
, pp. 1302-1313
-
-
Messmann, R.A.1
Vitetta, E.S.2
Headlee, D.3
-
19
-
-
77958490178
-
Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcyRllla-158 V/F polymorphism
-
Blum KA, Jung SH, Johnson JL et al. Serious pulmonary toxicity in patients with Hodgkin's lymphoma with SGN-30, gemcitabine, vinorelbine, and liposomal doxorubicin is associated with an FcyRllla-158 V/F polymorphism. Ann. Oncol. 21(11), 2246-2254 (2010).
-
(2010)
Ann. Oncol.
, vol.21
, Issue.11
, pp. 2246-2254
-
-
Blum, K.A.1
Jung, S.H.2
Johnson, J.L.3
-
20
-
-
80054111050
-
CD30-targeted antibody therapy
-
Younes A. CD30-targeted antibody therapy. Curr. Opin. Oncol. 23(6), 587-593 (2011).
-
(2011)
Curr. Opin. Oncol.
, vol.23
, Issue.6
, pp. 587-593
-
-
Younes, A.1
-
21
-
-
84855465227
-
A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30-positive hematologic malignancies
-
Fanale MA, Forero-Torres A, Rosenblatt JD et al. A Phase I weekly dosing study of brentuximab vedotin in patients with relapsed/ refractory CD30-positive hematologic malignancies. Clin. Cancer Res. 18(1), 248-255 (2012).
-
(2012)
Clin. Cancer Res.
, vol.18
, Issue.1
, pp. 248-255
-
-
Fanale, M.A.1
Forero-Torres, A.2
Rosenblatt, J.D.3
-
22
-
-
84863678237
-
Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a Phase II study
-
Pro B, Advani R, Brice P et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a Phase II study. J. Clin. Oncol. 30(18), 2190-2196 (2012).
-
(2012)
J. Clin. Oncol.
, vol.30
, Issue.18
, pp. 2190-2196
-
-
Pro, B.1
Advani, R.2
Brice, P.3
-
23
-
-
79959654218
-
Immunotoxins and other conjugates containing saporin-s6 for cancer therapy
-
Polito L, Bortolotti M, Pedrazzi M et al. Immunotoxins and other conjugates containing saporin-s6 for cancer therapy. Toxins (Basel) 3(6), 697-720.
-
Toxins (Basel)
, vol.3
, Issue.6
, pp. 697-720
-
-
Polito, L.1
Bortolotti, M.2
Pedrazzi, M.3
-
24
-
-
84957013985
-
A Phase II clinical trial of SGN-40 (dacetuzumab) monotherapy in relapsed diffuse large B-cell lymphoma
-
San Francisco, CA, USA 6-9 December
-
Advani R, De Vos S, Ansell SM et al. A Phase II clinical trial of SGN-40 (dacetuzumab) monotherapy in relapsed diffuse large B-cell lymphoma. Presented at: American Society of Hematology 2008 Annual Meeting. San Francisco, CA, USA 6-9 December 2008 (Abstract 1000).
-
(2008)
American Society of Hematology 2008 Annual Meeting.
-
-
Advani, R.1
De Vos, S.2
Ansell, S.M.3
-
25
-
-
84872047730
-
A pilot study of dacetuzumab (SGN-40, antihuCD40 mAb) in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
-
Forero-Torres A, Bartlett N, Beaven A et al. A pilot study of dacetuzumab (SGN-40, antihuCD40 mAb) in combination with rituximab and gemcitabine for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Leuk. Lymphoma 54(2), 277-283 (2013).
-
(2013)
Leuk. Lymphoma
, vol.54
, Issue.2
, pp. 277-283
-
-
Forero-Torres, A.1
Bartlett, N.2
Beaven, A.3
-
26
-
-
79955844043
-
Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory hodgkin or non-hodgkin lymphoma treated in a Phase Ia/II Clinical Trial (NCT00670592)
-
Orlando, FL, USA, 4-7 December
-
Freedman AS, Kuruvilla J, Assouline S et al. Clinical activity of lucatumumab (HCD122) in patients (pts) with relapsed/refractory hodgkin or non-hodgkin lymphoma treated in a Phase Ia/II Clinical Trial (NCT00670592). Presented at: ASH Annual Meeting 2010. Orlando, FL, USA, 4-7 December 2010 (Abstract 284).
-
(2010)
ASH Annual Meeting 2010.
-
-
Freedman, A.S.1
Kuruvilla, J.2
Assouline, S.3
-
27
-
-
34948824913
-
Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial
-
Gallamini A, Zaja F, Patti C et al. Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. Blood 110(7), 2316-2323 (2007).
-
(2007)
Blood
, vol.110
, Issue.7
, pp. 2316-2323
-
-
Gallamini, A.1
Zaja, F.2
Patti, C.3
|